Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sarah Vodopest (NPI 1780946194)

Field	Value
Entity Type	Individual
Organization	Sarah Vodopest
Address	5701 W 119th St Ste 209
City	Overland Park
State	KS
ZIP	66209
Taxonomy	Rheumatology Physician
NPI Enumerated	June 12, 2012

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

This provider’s billing is effectively single‑payer: Total Medicare revenue is $1.5M and there is no Medicaid billing on file, indicating Medicare dominates the payer mix for this NPI. The absence of any Medicaid activity suggests the practice’s patient panel or contracting is heavily skewed toward Medicare beneficiaries rather than dual‑eligible or Medicaid populations.

Revenue is highly concentrated in office‑administered biologic therapies: the precomputed top three Medicare codes by revenue (J0129, J3262, J0717) account for 63.8% of this provider’s total Medicare revenue. Individually those codes are J0129 $428.1K revenue (27.5%), J3262 $304.2K revenue (19.5%), and J0717 $262.4K revenue (16.8%), which together point to biologic infusion/injection services as the core revenue driver.

The service mix is consistent with a rheumatology infusion/biologic administration practice: top codes J0129 (abatacept), J3262 (tocilizumab), J0717 (certolizumab pegol), plus J1602 (golimumab) and J1745 (infliximab), are all high‑cost injectable or IV biologics. These codes characterize ongoing, in‑office management of chronic rheumatologic conditions rather than predominantly procedure‑based or surgical care.

Competitive standing across the top biologic codes is modestly scaled nationally rather than dominant: J0129 ranks #331 of 1221 providers nationally (73th percentile; typical, unremarkable volume for this code), J3262 ranks #174 of 618 (72th percentile; typical, unremarkable volume for this code), and J0717 ranks #281 of 848 (67th percentile; typical, unremarkable volume for this code). These ranks indicate respectable utilization of these drugs but not leading national market share for any single biologic.

Office E/M and infusion administration patterns show two distinct signals: 99214 has 662 claims and $58.3K revenue (3.7% of Medicare revenue) and is described as notably above typical national volume for this code, implying a higher‑than‑typical volume of established patient visits. At the same time, chemotherapy/infusion administration codes such as 96413 ($47.9K revenue, 3.1%) and 96401 ($21.2K revenue, 1.4%) appear with relatively elevated national percentiles but are labeled typical, unremarkable volume for those codes, supporting the interpretation that infusion services are an active, established part of clinic operations.

A handful of additional biologic and bone‑health agents contribute meaningful secondary revenue: J1602 $181.5K revenue (11.7%) and J1745 $162.2K revenue (10.4%) together add significant Medicare dollars beyond the top three, while J0897 (denosumab) contributes $81K (5.2%). The broader mix of IV and injectable specialty drugs reinforces dependency on in‑office drug administration rather than minor office procedures or facility services.

Tenure and operational stability are indicated by NPI enumeration: the provider was enumerated on 2012-06-12 (~14 years ago), suggesting an established billing history over more than a decade. This longevity, combined with concentrated biologic revenue, points to a stable clinical focus and a sustained Medicare patient base.

Low‑revenue/low‑volume codes make up a small tail of activity—examples include 96375 $228 revenue, J2930 $56 revenue, and J3301 $51 revenue—each described as typical, unremarkable volume for those codes. The presence of many small dollar codes alongside a heavy concentration in a few high‑cost biologics indicates a narrow service line orientation with most revenue tied to specialty drug administration rather than breadth of procedure types.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

15 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	12,590	$30	$428.1K
J3262	Injection, tocilizumab, 1 mg	60,850	$10	$304.2K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	65,600	$1	$262.4K
J1602	Injection, golimumab, 1 mg, for intravenous use	18,150	$10	$181.5K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	6,240	$30	$162.2K
J0897	Injection, denosumab, 1 mg	4,500	$20	$81K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	660	$90	$58.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	500	$100	$47.9K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	390	$50	$21.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	50	$120	$5.4K

Showing 1–10 of 15

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 15 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Sarah Vodopest — 1 of 15 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

15 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	3	20	8,000	$30	$291.5K
J3262	5	10	60,820	$1	$243K
J0717	4	10	51,600	$1	$200.4K
J1602	6	20	14,360	$10	$167.7K
J1745	4	20	3,110	$30	$96.9K
J0897	45	180	2,160	$20	$81.5K
96413	19	80	80	$90	$26.3K
99214	270	4,310	120	$70	$16.4K
96401	2	30	180	$50	$9K
99215	652	1,350	40	$100	$8.4K

Showing 1–10 of 15

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sarah Vodopest, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Carrie Mihordin	KS	Rheumatology Physician	$1.5M	$0
Jonathan Amos	KS	Rheumatology Physician	$951.5K	$0
Robyn Moran	KS	Rheumatology Physician	$859.1K	$0
Jaymi Anson	KS	Family Nurse Practitioner	$120.2K	$0

Nearby Providers

Other providers in the same ZIP code as Sarah Vodopest, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lamar Court Assisted Living	KS	Assisted Living Facility	$0	$3.4M
Mid-america Surgery Institute LLC	KS	Ambulatory Surgical Clinic/Center	$1.4M	$0
Thomas Hocker	KS	MOHS-Micrographic Surgery Physician	$1.1M	$0
Midwest Heart & Vascular Specialists, LLC	KS	Cardiovascular Disease Physician	$0	$1M
Playabilities For Sensational Kids, LLC	KS	Pediatric Occupational Therapist	$0	$790.8K
Ads Healthcare LLC	KS	Ambulatory Surgical Clinic/Center	$734K	$0
Michael Sokol	KS	Endocrinology, Diabetes & Metabolism Physician	$368.5K	$0
Cameron Ledford	KS	Orthopaedic Surgery Physician	$304.4K	$0
Daniel Kloster	KS	Interventional Pain Medicine Physician	$291.3K	$0
Rachel Sosland	KS	Cardiovascular Disease Physician	$248K	$0

Sarah Vodopest — Billing Profile & Reimbursement Data

Sign up for Sarah Vodopest — Billing Profile & Reimbursement Data policy alerts

Sarah Vodopest — Billing Profile & Reimbursement Data

Sign up for Sarah Vodopest — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References